Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland

Reuters

05/28

<a href="https://laohu8.com/S/CERS">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland

Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538547682"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538547682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538547682?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538547682","market":"nz","top_or_hot":-1,"title":"Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CERS\">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-28 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CERS\">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERS","symbol_name":"Cerus Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLbMK5dw:1","article_id":"2538547682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538547682","pubTimestamp":1748435460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety  and the Swiss Agency for Therapeutic Products  have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERS":"Cerus Corporation","BK4198":"医疗保健用品"},"translate_title":"Cerus Corporation的INT200设备在法国和瑞士获得监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERS":0.9},"content_text":"Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    \n\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}